Health-care companies rose as traders sought out fast-growing biotech and pharmaceutical companies.
KalVista Pharmaceuticals shares tumbled after the company halted a mid-stage trial for the prevention of attacks in people with hereditary angioedema.
The U.S. Centers for Disease Control and Prevention has dropped its country-by-country Covid-19 travel health notices that it began issuing early in the pandemic.
Pfizer said its drug Talzenna showed promise in a late-stage trial on prostate-cancer patients.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
10-04-22 1655ET
